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It is thought that cancer cells engage in Warburg metabolism to meet intrinsic biosynthetic re-
quirements of cell growth and proliferation. Papers by Chang et al. and Ho et al. show that Warburg
metabolism enables tumor cells to restrict glucose availability to T cells, suppressing anti-tumor
immunity.In the presence of oxygen, most differen-
tiated cells utilize mitochondrial oxidative
phosphorylation to generate energy in
the form of adenosine triphosphate (ATP)
that can be used to sustain cellular pro-
cesses. In the absence of oxygen, such
cells revert to much less efficient glycol-
ysis as a means of ATP production. Can-
cer cells often utilize glycolysis despite
the presence of oxygen (aerobic glycol-
ysis or the ‘‘Warburg effect’’) (Warburg,
1956). While less efficient at producing
energy, it is thought that this form ofmeta-
bolism supports the macromolecular
requirements of cell growth and prolifera-
tion. Thus, the field has primarily focused
on Warburg metabolism as an adaptation
that confers intrinsic growth advantages
to tumor cells themselves. However,
cancer cells may consume nutrients,
particularly glucose, in excess of their
requirement to sustain proliferation and
cell growth (Vander Heiden et al., 2009).
This raises the possibility that nutrient
consumption serves additional roles to
meeting the intrinsic bioenergetic and
biosynthetic requirements of cancer cells.
In this issue of Cell, Ho et al. (2015) and
Chang et al. (2015) show that Warburg
metabolism provides tumor cells with
a cell-extrinsic advantage, promoting
depletion of extracellular glucose which
renders tumor-infiltrating T cells dysfunc-
tional.
In both studies, glycolysis within tumor
cells is shown to cause depletion of
extracellular glucose which restricts
glucose availability to T cells. Decreased
glucose availability causes suppres-
sion of glycolytic metabolism within
T cells, and this is associated with
decreased effector function (Figure 1,1206 Cell 162, September 10, 2015 ª2015 Elleft). Ho et al. identify a mechanism by
which glucose metabolism directly con-
trols effector function. The authors find
that T cell receptor (TCR)-induced Ca2+
flux is markedly dependent upon extra-
cellular glucose and glucose metabolism
by T cells. Sarco/endoplasmic reticulum
(ER) Ca2+-ATPase (SERCA) is an ATP-
dependent Ca2+ channel that pumps
Ca2+ from the cytoplasm into the ER.
Extracellular glucose is shown to pro-
mote accumulation of the glycolytic
metabolite, phosphoenolpyruvate (PEP),
which inhibits SERCA-dependent evacu-
ation of Ca2+ from the cytosol into the
ER, thereby increasing TCR-induced
Ca2+ flux and effector function (Figure 1,
right). This observation adds to a
growing list of examples whereby meta-
bolic processes directly control the
outcome of T cell activation (Chang
et al., 2013; MacIver et al., 2013).
That tumor cell glycolysis directly sup-
presses T cells raises the possibility
that tumor metabolism can be thera-
peutically manipulated to improve im-
mune function within tumors. Check-
point blockade immunotherapy with
anti-PD-L1 antibodies is thought to
work by limiting inhibitory PD-1 signaling
received by tumor-specific T cells (Keir
et al., 2008). Chang et al. made the sur-
prising observation that PD-1 ligand
(PD-L1) expressed by tumor cells pro-
vides a constitutive ‘‘reverse signal’’
that promotes tumor cell glycolysis
through activation of the AKT/mTOR
pathway (Figure 1, left). Treatment of
tumor cells with therapeutic anti-PD-
L1 antibodies attenuates glycolysis by
triggering PD-L1 endocytosis (Figure 1,
right). Remarkably, two other check-sevier Inc.point-blockade antibodies, anti-PD-1
and anti-CTLA-4, are also shown to
cause changes in extracellular glucose
concentrations within tumors, though
mechanisms for these observations are
unclear. That PD-L1 expression causes
constitutive activation of the Akt/mTOR
pathway has important implications for
understanding tumor cell biology and
tumor-host interactions, and it will be
important to characterize precise mol-
ecular mechanisms by which PD-L1
constitutively activates the Akt/mTOR
pathway. Given that immune checkpoint
blockade elicits durable clinical re-
sponses and improves survival in pa-
tients with certain metastatic cancers
(Larkin et al., 2015; Topalian et al.,
2012), it is relevant to measure the effect
of checkpoint blockade antibodies on
intratumoral nutrient availability and
T cell metabolism in patients and cor-
relate this with clinical outcomes.
Further, it will be important to dissect
the effects of checkpoint blockade on
inhibitory T cell signaling versus tumor
cell metabolism.
Instead of manipulating tumor cell
metabolism, Ho et.al. suggest an alter-
nate approach to improve T cell func-
tion by mimicking nutrient availability
within transferred T cells during adop-
tive cell therapy (ACT). Phospho-
enolpyruvate Carboxykinase (PCK1)
converts oxaloacetate into PEP. By
overexpressing Pck1 in transferred
T cells, Ho et al. are able to artificially
increase PEP levels, restoring TCR-
induced Ca2+ flux and anti-tumor
T cell function despite the presence of
low environmental glucose levels within
tumors. Intriguingly, blocking glucose
Figure 1. Nutrient Competition between Tumor Cells and T Cells Controls Immune Function within Tumors
Schematic depicting glucose metabolism and cellular signaling in highly glycolytic progressor tumors and repressor tumors undergoing therapy. In
the progressor tumor (left), constitutive activation of the Akt/mTOR pathway by PD-L1 expressed on tumor cells causes high levels of tumor cell
glycolysis and absorption of extracellular glucose. Decreased extracellular glucose levels causes impaired glycolysis in T cells, wherein depletion of
the glycolytic metabolite PEP causes unrestrained SERCA activity, sequestration of cytoplasmic Ca2+ into the ER and impairment of TCR-induced Ca2+
flux and effector function. In the regressor tumor (right), therapeutic anti-PD-L1 antibodies bind to PD-L1 causing its endocytosis and inactivation.
Loss of constitutive PD-L1 signaling leads to decreased activation of the Akt-mTOR pathway decreased tumor cell glycolysis and increased extra-
cellular glucose concentrations. Increased extracellular glucose drives T cell glycolysis, replenishing PEP levels, inhibiting SERCA-dependent seques-
tration of cytoplasmic Ca2+ and promoting TCR-induced Ca2+ flux and anti-tumor effector functions. Alternatively, constitutive overexpression of
PCK1 in adoptively transferred T cells increases availability of PEP leading to inhibition of SERCA, increased anti-tumor effector function and tumor
regression.metabolism during expansion of T cells
for adoptive immunotherapy withholds
effector differentiation and promotes
differentiation of memory cells which
mediate superior tumor clearance (Su-
kumar et al., 2013). These findings pro-
vide striking examples of how modu-
lating T cell metabolism can improve
the outcome of adoptive cell therapy
for cancer.
Taken together, the two new studies
provide compelling evidence that can-
cer cells subvert the metabolic charac-teristics of the tumor microenvironment
to shape immune responses within
tumors. The results also provide an
explanation of how nutrient consump-
tion in excess of the bioenergetic and
biosynthetic requirements may benefit
cancer cells. As Warburg’s original
observation is revisited in ever new re-
incarnations, it remains to be seen
whether insights from the field of im-
munometabolism will change the game
at this new front in our war against
cancer.Cell 162, SepREFERENCES
Chang, C.H., Curtis, J.D., Maggi, L.B., Jr., Faubert,
B., Villarino, A.V., O’Sullivan, D., Huang, S.C., van
der Windt, G.J., Blagih, J., Qiu, J., et al. (2013).
Cell 153, 1239–1251.
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M.D.,
Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gu-
bin, M.W., and van der Windt, G.J.W. (2015). Cell
162, this issue, 1229–1241.
Ho, P.-C., Bihuniak, J.D., Macintyre, A.N., Staron,
M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Mi-
cevic, G., Perales, J.C., et al. (2015). Cell 162, this
issue, 1217–1228.tember 10, 2015 ª2015 Elsevier Inc. 1207
Keir, M.E., Butte, M.J., Freeman, G.J., and
Sharpe, A.H. (2008). Annu. Rev. Immunol. 26,
677–704.
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob,
J.J., Cowey, C.L., Lao, C.D., Schadendorf, D.,
Dummer, R., Smylie, M., Rutkowski, P., et al.
(2015). N. Engl. J. Med. 373, 23–34.1208 Cell 162, September 10, 2015 ª2015 ElMacIver, N.J., Michalek, R.D., and Rathmell, J.C.
(2013). Annu. Rev. Immunol. 31, 259–283.
Sukumar, M., Liu, J., Ji, Y., Subramanian, M.,
Crompton, J.G., Yu, Z., Roychoudhuri, R., Palmer,
D.C., Muranski, P., Karoly, E.D., et al. (2013).
J. Clin. Invest. 123, 4479–4488.
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Get-
tinger, S.N., Smith, D.C., McDermott, D.F., Powd-sevier Inc.erly, J.D., Carvajal, R.D., Sosman, J.A., Atkins,
M.B., et al. (2012). N. Engl. J. Med. 366, 2443–
2454.
Vander Heiden, M.G., Cantley, L.C., and Thomp-
son, C.B. (2009). Science 324, 1029–1033.
Warburg, O. (1956). Science 123, 309–314.Single-Cell Analysis: The Differences That KillSavasx Tay1,2,*
1Department of Biosystems Science and Engineering, ETH Zurich, Basel 4058, Switzerland
2Institute for Molecular Engineering, University of Chicago, Chicago 60637, USA
*Correspondence: tays@uchicago.edu
http://dx.doi.org/10.1016/j.cell.2015.08.053
Using single-cell RNA sequencing, Avraham et al. investigate how variability in macrophage res-
ponse to infection is controlled by variability within the pathogen population. They find that hetero-
geneous expression of the Salmonella virulence factor PhoP and subsequent cell-wall modifica-
tions lead to the bimodal induction of the interferon-response in infected macrophages.What exactly happens when pathogens
penetrate the outer defenses of tissues
and start infecting various cells? Since
the dawn of modern biology, the battle
between pathogens and immune cells
has been a central focus, and thanks to
powerful new methods that analyze indi-
vidual cells, we are taking a fresh look at
our understanding of infection and immu-
nity. Unlike what traditional population-
averaged analyses show, the outcome
of pathogen exposure is vastly more
complex at the individual-cell level. For
example, some host cells completely
avoid infection and survive. Other cells
become infected and die, survive with
the presence of bacteria inside them,
or completely clear the pathogens and
function normally afterward. The intri-
cate workings of the molecular pathways
determining infection and immunity are
largely unclear. In this issue of Cell,
Hung and colleagues take a new look at
this fundamental problem using single-
cell analysis and ask whether variability
in infection outcomes can be explained
by the variability among individual bacte-
ria (Avraham et al., 2015). This is a unique
approach as compared to most work in
the newly emerging field of single-cellimmunology. In explaining heterogeneous
infection outcomes, the field tends to
focus on the state of the host and environ-
ment (Snijder et al., 2009), rather than pre-
existing variability in the pathogen.
Hung’s team focus on the infection of
macrophages—first responders of the
innate immune system—with Salmonella
typhimurium, a pathogen that causes
typhoid fever and food poisoning in hu-
mans. Despite a century of antibiotic
treatment and improved hygiene, basic
pathogens such as Salmonella remain a
major health problem, especially in the
developing world. Even the developed
world is at risk from these basic infec-
tions, as evidenced by thousands of
salmonella infections every year in the
USA alone and the recent E. coli outbreak
in Germany that killed 50 people over the
course of a few weeks.
Salmonella typhimurium has special-
ized molecular tools to avoid, resist, and
even hijack the mammalian immune
system. Macrophages recognize these
pathogen-associated factors and mount
transcriptional programs to change their
physiology and clear the pathogen. Indi-
vidual Salmonella cells can vary in the
manner they express virulence factors.Can the variability in infection outcomes
be explained by the variability within the
pathogen population? And if so, what
virulence factors control this variability?
To answer these questions, Avraham
et al. first use fluorescent single-cell mi-
croscopy to distinguish various infection
outcomes: When mixed with salmonella,
the macrophages could remain unin-
fected, or become infected with either
live or dead bacteria inside. They isolate
these single macrophages and use
state-of-the-art RNA sequencing (RNA-
seq) to determine their transcriptional
state by measuring the expression of
535 immune response genes. These
genes cluster into distinct groups; how-
ever, one cluster shows much higher
expression variability between individual
cells. These variable genes were related
to innate immune recognition of the bac-
terial virulence factors, including bacterial
cell-wall components like lipopolysac-
charide (LPS), hinting that the LPS/TLR4
signaling pathway underlies phenotype
variability. In particular, Type 1 interferon
(IFN) response exhibit bimodal expres-
sion in host macrophages, with roughly
one third of cells expressing IFN genes
at high levels, and the rest at low levels
